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INTRODUCTION
Hemorrhagic and thrombotic disorders are largely
mediated by congenital or acquired abnormalities of
blood coagulation, platelet number, or platelet function.
Abnormal bleeding can result from excessive expression
of plasminogen activators or from deficiencies of
fibrinolysis inhibitors.1 Most inherited bleeding disorders
result from genetic defects that reduce hemostatic protein
expression, secretion, or function.2 Inherited conditions
that cause bleeding by increasing gene expression are
uncommon and include Quebec platelet disorder (QPD),
an autosomal dominant disorder with high and possibly
complete penetrance.3 QPD is associated with a unique
gain-of-function abnormality in fibrinolysis due to
increased platelet stores of urokinase plasminogen
activator (uPA) without systemic fibrinolysis or increased
uPA in plasma, urine, or CD34_ hematopoietic
progenitors.4-6 QPD increases risks for a number of
bleeding symptoms, including delayed-onset bleeding
after hemostatic challenges that respond only to
fibrinolytic inhibitor therapy. Diagnostic tests for QPD
include assays for increased platelet uPA and alpha
granule protein degradation from intraplatelet plasmin
generation,7 platelet function test is assessed with the
help of platelet aggregation assay by exposing platelets
to various stimulants like ADP, arachidonic acid,
collagen, epinephrine, thrombin, and ristocetin. In QBD,
platelets show very abnormal aggregation with
epinephrine because there is defect in alpha granules
proteolysis of proteins and a deficiency of  alpha granule
multimerin, a protein that binds factor V within granule
and leads to a decreased content of factor V and several
other proteins like fibrinogen, vWF etc.
This case report describes a rare clinical condition in a
young female.
CASE REPORT
A 33 years old woman presented with generalized
weakness, weight loss, pallor and history of epistaxis
and gum bleeding since childhood and menorrhagia
after puberty. She also had increased blood loss after
birth of her all three children who were born by normal
delivery. Patient had undergone multiple blood
transfusions in her past history for low hemoglobin. She
had 5 sisters and 6 brothers. There was positive family
history for bleeding episodes among her siblings (two
sisters), but their workup for bleeding disorders was not
done. There was no history of any bleeding disorders
among parents, her parents are not available so
pedigree tracing is not possible but assumedly her
mother was as the affected parent for pedigree tracing
(Figure 1). 
On examination she was thin, lean and pale. The rest of
physical examination was normal except for having easy
bruising after needle prick. Chest examination showed
dull percussion note over the left lower lung base.
On investigations, chest X-ray was done which showed
left sided mild pleural effusion. Workup for pleural effusion
ABSTRACT
A case of Quebec platelet disorder is hereby reported. A 33 years old woman presented with history of epistaxis and gum
bleeding since childhood and menorrhagia and bleeding per vaginum after puberty, also had history of excessive blood
loss after birth of child. Her coagulation profile was normal but platelet function testing by platelet aggregation assay
showed abnormal aggregation of platelet with epinephrine. This type of response is seen in “Quebec platelet disorder”
which is a rare autosomal dominant disorder of platelet function characterized by increased bleeding after any injury or
trauma.
Key words: Quebec platelet disorder.   Platelet function test.   Bleeding  time.   Abnormal aggregation.   Epinephrine.
Department of Medicine, The Aga Khan University Hospital,
Karachi.
Correspondence: Dr. Anwar Hussain Abbasi, House No. 131,
Block-E, Unit No.8, Latifabad, Hyderabad.
E-mail: anwar.abbasi@aku.edu   
Received  June  24, 2009; accepted March 12, 2010.
Quebec Platelet Disorder
Anwar Hussain Abbasi, Quratulain Shaikh and Syed Ather Hussain
CASE REPORT
Figure 1:  Pedigree tracing for Quebec platelet disorder in the reported case.
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raised strong suspicion of tuberculosis as effusion was
exudative lymphocytic, which was augmented with
positive tuberculin skin test (Mantoux test). She was
started on anti-tuberculosis treatment. 
Further workup was done due to her symptoms of
bleeding. Her complete blood count showed hemoglobin
of 5.2 g/dl with mean corpuscular volume of 56 FL. The
white cell and reticulocyte count were normal. Peripheral
smear showed microcytic hypochromic anemia. Her
platelet count was normal. Coagulation profile showed
normal PT and APTT which bleeding time (BT) was
more than 9 minutes. Platelet function testing was done
by platelet agregometry which showed normal response
to other factors like collagen, ADP, thrombin, but  an
abnormal aggregation response to epinephrine. All
other factor assays like factor VIII, vWF, factor XIII were
normal. This type of platelet response is seen in Quebec
platelet disorder. So she was diagnosed to have Quebec
platelet disorder and was started on fibrnolysis inhibitors
(tranexamic acid) after which her gum bleeding stopped
but she needed blood transfusion for severe anemia.
DISCUSSION
Quebec Platelet Disorder (QPD) is an autosomal
dominant bleeding disorder which is more prevalent in
province of Quebec in Canada.8 The disorder is
characterized by large amounts of the fibrinolytic
enzyme urokinase-type plasminogen activator (u-PA) in
platelets. Consequently, stored platelet plasminogen is
converted to plasmin, which is thought to play a role in
degrading a number of proteins stored in platelet α-
granules. These proteins include platelet factor V, Von
Willebrand factor, fibrinogen, thrombospondin-1, and
osteonectin. There is also a quantitative deficiency in the
platelet protein multimerin 1 (MMRN1). Furthermore, upon
QPD platelet activation, u-PA can be released into
forming clots and accelerate clot lysis, resulting in
delayed-onset bleeding (12-24 hours after injury).
Individuals with QPD are at risk for experiencing a
number of bleeding symptoms, including joint bleeds,
hematuria, and large bruising. This patient likewise also
experienced bleeding episodes especially from gums,
and menorrhagia. The genetic cause of QPD has not yet
been determined. Whether the abnormal bleeding in this
disorder results from the degradation of platelet
hemostatic factors, premature lysis of thrombi due to
u-PA release from platelets, or both, is unresolved. However,
studies of transgenic mice with platelet-specific over-
expression of u-PA suggest that premature clot lysis due
to localized release of u-PA from platelets is the
predominant cause of bleeding.9
In bleeding patients with the factor V Quebec platelet
disorder, platelet transfusions are generally without
effect; fibrinolytic inhibitors are reported to be effective.8
Tranexamic acid and aminocaproic acid are lysine
analogues that bind to the kringle domains of plasminogen
and disrupt interactions between plasminogen (and
plasmin) and lysine residues within fibrin. Uptill now
tranexamic acid has benefitted in resolving bleeding
episodes in our patients. A meta-analysis of clinical trials
indicated that lysine analogues significantly reduce
perioperative blood loss in patients undergoing coronary
artery bypass grafting with cardiopulmonary bypass,
without increasing the incidence of myocardial infarction.10
This lady, admitted with history of bleeding gums,
epistaxis and menorrhagia and history of multiple blood
transfusions, was diagnosed to have “Quebec platelet
disorder” on the basis of history, examination and
laboratory findings of increased bleeding time and on
platelet function testing by platelet aggregation assay
showing abnormal aggregation to epinephrine. She was
managed with giving lysine analogues like Tranexamic
acid which act as fibrinolytic inhibitors. She responded
well to treatment and her bleeding symptoms resolved.
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